Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@EgidiusLambrech Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::404367469.png) @EgidiusLambrech E Lambrechts

E Lambrechts posts on X about $gmab, $mrus, $jnj, combo the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::404367469/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::404367469/c:line/m:interactions.svg)

- X Week XXXXX +113%
- X Month XXXXX +61%
- X Months XXXXXX -XX%
- X Year XXXXXX -XXXX%

### Mentions: XX [#](/creator/twitter::404367469/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::404367469/c:line/m:posts_active.svg)

- X Week XX +11%
- X Month XX +100%
- X Months XX +29%
- X Year XXX +41%

### Followers: XXX [#](/creator/twitter::404367469/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::404367469/c:line/m:followers.svg)

- X Week XXX no change
- X Month XXX -XXXX%
- X Months XXX +2.40%
- X Year XXX -XX%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::404367469/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::404367469/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::404367469/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXXX%

**Social topic influence**
[$gmab](/topic/$gmab) #5, [$mrus](/topic/$mrus) #7, [$jnj](/topic/$jnj) #393, [combo](/topic/combo) 4.76%, [te](/topic/te) 4.76%, [people with](/topic/people-with) 4.76%, [$novo](/topic/$novo) 4.76%, [announces](/topic/announces) 4.76%, [targets](/topic/targets) XXXX%

**Top accounts mentioned or mentioned by**
[@luciusjameson](/creator/undefined) [@genmab](/creator/undefined) [@cision](/creator/undefined) [@davidmygind](/creator/undefined) [@fyee0308](/creator/undefined) [@bertrandbio](/creator/undefined)

**Top assets mentioned**
[Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Johnson & Johnson (JNJ)](/topic/$jnj)
### Top Social Posts [#](/creator/twitter::404367469/posts)
---
Top posts by engagements in the last XX hours

"$GMAB #Genmab"  
[X Link](https://x.com/EgidiusLambrech/status/1978101436350108115) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-14T14:11Z XXX followers, XXX engagements


"Nearly half of women with hard-to-treat #endometrial cancer responded to Rina-S (#rinatabart sesutecan) in a Phase X clinical trial. #Genmab $GMAB"  
[X Link](https://x.com/EgidiusLambrech/status/1980995008695251088) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-22T13:49Z XXX followers, XXX engagements


"Promising Clinical Developments in #Genmabs Portfolio Reinforce Buy Rating Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab and keeping the price target at $XXXXX. $GMAB"  
[X Link](https://x.com/EgidiusLambrech/status/1980595729703002148) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-21T11:23Z XXX followers, XXX engagements


"Deense farmaceut verrast met overname #Merus: #Genmab is anderen te snel af geweest. $GMAB $MRUS #BNR"  
[X Link](https://x.com/EgidiusLambrech/status/1972718207959027996) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-09-29T17:40Z XXX followers, XXX engagements


"Novo Nordisk has submitted an application to the FDA seeking approval of #Mim8 for the treatment of people with hemophilia A. $NOVO $GMAB #Genmab #Royalties #denecimig"  
[X Link](https://x.com/EgidiusLambrech/status/1973260900758069466) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-01T05:37Z XXX followers, XXX engagements


"#Merus Announces #Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics $GMAB #Genmab"  
[X Link](https://x.com/EgidiusLambrech/status/1977775373044556257) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-13T16:36Z XXX followers, XXX engagements


"Teclistamab $JNJ $GMAB #Genmab Tecvayli"  
[X Link](https://x.com/EgidiusLambrech/status/1978719238467493965) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-16T07:06Z XXX followers, XXX engagements


"#Petosemtamab shows first colorectal promise $MRUS $GMAB #Genmab"  
[X Link](https://x.com/EgidiusLambrech/status/1978722419754815886) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-16T07:19Z XXX followers, XXX engagements


"$GMAB #Genmab Tecvayli/Darzalex combo"  
[X Link](https://x.com/EgidiusLambrech/status/1978800685526474763) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-16T12:30Z XXX followers, XXX engagements


"Fast and confident follow up by #Genmab on the Merus takeover. $GMAB clearly has no doubts on petosemtamab. Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V"  
[X Link](https://x.com/EgidiusLambrech/status/1980682763394048489) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-21T17:09Z XXX followers, XXX engagements


"@LuciusJameson I assume Genmab has the deepest understanding of Rybrevant capabilities after JNJ they even created both arms. Merus itself has MCLA-129 -EGFR x c-MET biclonics which data Genmab will have seen"  
[X Link](https://x.com/EgidiusLambrech/status/1980697399321334062) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-21T18:07Z XXX followers, XXX engagements


"@LuciusJameson in addition they have GEN1286 from Profound which they said was 'pre-clinically far outperforming amivantamab and other EGFR CMET'. Not sure if they have seen HNSCC data with those but it very hard for me to believe Genmab did not seriously consider amivantamab competition"  
[X Link](https://x.com/EgidiusLambrech/status/1980697502027231482) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-21T18:07Z XXX followers, XXX engagements


"@LuciusJameson i don't know assume they'll wait for the data; we know they have been rather ruthless ditching programs that were not up to their high standards. Remember they also cancelled plans to prodeed with Tisotumab into head/neck it is a field they claim to be very knowledgeable about"  
[X Link](https://x.com/EgidiusLambrech/status/1980702172556792219) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-21T18:26Z XXX followers, XX engagements


"#Genmab accelerates its biopharma strategy with #Merus N.V. as the catalyst. by @davidmygind #Genmab $GMAB $MRUS"  
[X Link](https://x.com/EgidiusLambrech/status/1981313063161668005) [@EgidiusLambrech](/creator/x/EgidiusLambrech) 2025-10-23T10:53Z XXX followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@EgidiusLambrech Avatar @EgidiusLambrech E Lambrechts

E Lambrechts posts on X about $gmab, $mrus, $jnj, combo the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

  • X Week XXXXX +113%
  • X Month XXXXX +61%
  • X Months XXXXXX -XX%
  • X Year XXXXXX -XXXX%

Mentions: XX #

Mentions Line Chart

  • X Week XX +11%
  • X Month XX +100%
  • X Months XX +29%
  • X Year XXX +41%

Followers: XXX #

Followers Line Chart

  • X Week XXX no change
  • X Month XXX -XXXX%
  • X Months XXX +2.40%
  • X Year XXX -XX%

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #


Social category influence stocks XXXX% finance XXXX%

Social topic influence $gmab #5, $mrus #7, $jnj #393, combo 4.76%, te 4.76%, people with 4.76%, $novo 4.76%, announces 4.76%, targets XXXX%

Top accounts mentioned or mentioned by @luciusjameson @genmab @cision @davidmygind @fyee0308 @bertrandbio

Top assets mentioned Merus N.V. Common Shares (MRUS) Johnson & Johnson (JNJ)

Top Social Posts #


Top posts by engagements in the last XX hours

"$GMAB #Genmab"
X Link @EgidiusLambrech 2025-10-14T14:11Z XXX followers, XXX engagements

"Nearly half of women with hard-to-treat #endometrial cancer responded to Rina-S (#rinatabart sesutecan) in a Phase X clinical trial. #Genmab $GMAB"
X Link @EgidiusLambrech 2025-10-22T13:49Z XXX followers, XXX engagements

"Promising Clinical Developments in #Genmabs Portfolio Reinforce Buy Rating Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab and keeping the price target at $XXXXX. $GMAB"
X Link @EgidiusLambrech 2025-10-21T11:23Z XXX followers, XXX engagements

"Deense farmaceut verrast met overname #Merus: #Genmab is anderen te snel af geweest. $GMAB $MRUS #BNR"
X Link @EgidiusLambrech 2025-09-29T17:40Z XXX followers, XXX engagements

"Novo Nordisk has submitted an application to the FDA seeking approval of #Mim8 for the treatment of people with hemophilia A. $NOVO $GMAB #Genmab #Royalties #denecimig"
X Link @EgidiusLambrech 2025-10-01T05:37Z XXX followers, XXX engagements

"#Merus Announces #Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics $GMAB #Genmab"
X Link @EgidiusLambrech 2025-10-13T16:36Z XXX followers, XXX engagements

"Teclistamab $JNJ $GMAB #Genmab Tecvayli"
X Link @EgidiusLambrech 2025-10-16T07:06Z XXX followers, XXX engagements

"#Petosemtamab shows first colorectal promise $MRUS $GMAB #Genmab"
X Link @EgidiusLambrech 2025-10-16T07:19Z XXX followers, XXX engagements

"$GMAB #Genmab Tecvayli/Darzalex combo"
X Link @EgidiusLambrech 2025-10-16T12:30Z XXX followers, XXX engagements

"Fast and confident follow up by #Genmab on the Merus takeover. $GMAB clearly has no doubts on petosemtamab. Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V"
X Link @EgidiusLambrech 2025-10-21T17:09Z XXX followers, XXX engagements

"@LuciusJameson I assume Genmab has the deepest understanding of Rybrevant capabilities after JNJ they even created both arms. Merus itself has MCLA-129 -EGFR x c-MET biclonics which data Genmab will have seen"
X Link @EgidiusLambrech 2025-10-21T18:07Z XXX followers, XXX engagements

"@LuciusJameson in addition they have GEN1286 from Profound which they said was 'pre-clinically far outperforming amivantamab and other EGFR CMET'. Not sure if they have seen HNSCC data with those but it very hard for me to believe Genmab did not seriously consider amivantamab competition"
X Link @EgidiusLambrech 2025-10-21T18:07Z XXX followers, XXX engagements

"@LuciusJameson i don't know assume they'll wait for the data; we know they have been rather ruthless ditching programs that were not up to their high standards. Remember they also cancelled plans to prodeed with Tisotumab into head/neck it is a field they claim to be very knowledgeable about"
X Link @EgidiusLambrech 2025-10-21T18:26Z XXX followers, XX engagements

"#Genmab accelerates its biopharma strategy with #Merus N.V. as the catalyst. by @davidmygind #Genmab $GMAB $MRUS"
X Link @EgidiusLambrech 2025-10-23T10:53Z XXX followers, XX engagements

creator/x::EgidiusLambrech
/creator/x::EgidiusLambrech